Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Nicotinic | 15 | 2024 | 114 | 3.910 |
Why?
|
| Peptide Fragments | 9 | 2025 | 301 | 3.060 |
Why?
|
| Calcium | 15 | 2018 | 487 | 2.390 |
Why?
|
| Presynaptic Terminals | 9 | 2014 | 54 | 2.130 |
Why?
|
| Neuroprotective Agents | 5 | 2025 | 267 | 1.890 |
Why?
|
| Neurons | 11 | 2025 | 1246 | 1.760 |
Why?
|
| Oligopeptides | 2 | 2025 | 108 | 1.040 |
Why?
|
| Alzheimer Disease | 6 | 2023 | 972 | 1.010 |
Why?
|
| Hippocampus | 8 | 2025 | 591 | 0.970 |
Why?
|
| Dendritic Spines | 1 | 2025 | 35 | 0.910 |
Why?
|
| Animals | 41 | 2025 | 16695 | 0.860 |
Why?
|
| Mice | 25 | 2025 | 6490 | 0.830 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 4 | 2011 | 7 | 0.770 |
Why?
|
| Homeostasis | 4 | 2020 | 193 | 0.670 |
Why?
|
| Neuronal Plasticity | 3 | 2018 | 126 | 0.660 |
Why?
|
| Synaptosomes | 6 | 2011 | 22 | 0.630 |
Why?
|
| Nicotine | 8 | 2011 | 290 | 0.630 |
Why?
|
| Mice, Inbred C57BL | 15 | 2025 | 1804 | 0.620 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 5 | 2018 | 66 | 0.590 |
Why?
|
| Drug Discovery | 1 | 2019 | 106 | 0.570 |
Why?
|
| Fear | 3 | 2017 | 271 | 0.550 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2020 | 95 | 0.510 |
Why?
|
| Microglia | 3 | 2023 | 204 | 0.470 |
Why?
|
| Mice, Transgenic | 5 | 2023 | 658 | 0.460 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 189 | 0.440 |
Why?
|
| Calcium Channels | 2 | 2007 | 74 | 0.430 |
Why?
|
| Neostriatum | 2 | 2006 | 28 | 0.420 |
Why?
|
| Receptors, Aryl Hydrocarbon | 3 | 2021 | 49 | 0.400 |
Why?
|
| Liver | 5 | 2021 | 503 | 0.380 |
Why?
|
| Male | 25 | 2025 | 22779 | 0.370 |
Why?
|
| Synapses | 3 | 2019 | 184 | 0.370 |
Why?
|
| Purkinje Cells | 1 | 2011 | 19 | 0.360 |
Why?
|
| Amino Acids, Aromatic | 1 | 2011 | 7 | 0.360 |
Why?
|
| Cerebellum | 1 | 2011 | 78 | 0.360 |
Why?
|
| Amyloid | 1 | 2011 | 66 | 0.340 |
Why?
|
| Receptors, Serotonin | 2 | 2001 | 25 | 0.340 |
Why?
|
| Cerebral Cortex | 2 | 2009 | 303 | 0.320 |
Why?
|
| Membrane Microdomains | 1 | 2010 | 53 | 0.320 |
Why?
|
| Schools, Medical | 3 | 2018 | 208 | 0.310 |
Why?
|
| Dopamine | 2 | 2011 | 272 | 0.310 |
Why?
|
| Models, Biological | 1 | 2013 | 711 | 0.310 |
Why?
|
| Receptors, Presynaptic | 2 | 2006 | 4 | 0.300 |
Why?
|
| Microscopy, Confocal | 5 | 2010 | 223 | 0.290 |
Why?
|
| Reactive Oxygen Species | 3 | 2017 | 518 | 0.290 |
Why?
|
| Cell Line, Tumor | 4 | 2017 | 2598 | 0.280 |
Why?
|
| TRPC Cation Channels | 1 | 2007 | 7 | 0.280 |
Why?
|
| GTP-Binding Proteins | 2 | 2018 | 58 | 0.280 |
Why?
|
| Corpus Striatum | 3 | 2009 | 119 | 0.280 |
Why?
|
| Benzofurans | 3 | 2021 | 22 | 0.270 |
Why?
|
| Cells, Cultured | 4 | 2025 | 1617 | 0.270 |
Why?
|
| Adenosine Triphosphatases | 1 | 2007 | 83 | 0.270 |
Why?
|
| Mice, Knockout | 6 | 2021 | 1010 | 0.260 |
Why?
|
| tau Proteins | 2 | 2020 | 182 | 0.260 |
Why?
|
| Neocortex | 2 | 2003 | 27 | 0.250 |
Why?
|
| Inflammation | 2 | 2023 | 729 | 0.250 |
Why?
|
| Rats | 9 | 2011 | 3701 | 0.250 |
Why?
|
| Nicotinic Agonists | 4 | 2009 | 87 | 0.250 |
Why?
|
| Cell Line | 3 | 2020 | 1416 | 0.240 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2006 | 45 | 0.240 |
Why?
|
| Metabolomics | 5 | 2020 | 90 | 0.240 |
Why?
|
| Prefrontal Cortex | 1 | 2007 | 160 | 0.240 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2006 | 83 | 0.240 |
Why?
|
| Signal Transduction | 5 | 2019 | 2111 | 0.230 |
Why?
|
| Molecular Biology | 2 | 2015 | 47 | 0.220 |
Why?
|
| Luteolin | 2 | 2021 | 10 | 0.220 |
Why?
|
| Bungarotoxins | 4 | 2011 | 22 | 0.210 |
Why?
|
| Gliosis | 1 | 2023 | 25 | 0.200 |
Why?
|
| Humans | 14 | 2024 | 42163 | 0.200 |
Why?
|
| Neuroblastoma | 2 | 2001 | 134 | 0.200 |
Why?
|
| Bile Acids and Salts | 3 | 2018 | 37 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2009 | 1737 | 0.190 |
Why?
|
| Developing Countries | 1 | 2022 | 112 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 1554 | 0.190 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 2 | 2018 | 10 | 0.180 |
Why?
|
| Oxidative Stress | 3 | 2017 | 990 | 0.180 |
Why?
|
| Lipogenesis | 1 | 2021 | 19 | 0.180 |
Why?
|
| Nematode Infections | 1 | 2021 | 2 | 0.180 |
Why?
|
| Tylenchoidea | 1 | 2021 | 4 | 0.180 |
Why?
|
| Synaptic Transmission | 2 | 2018 | 156 | 0.180 |
Why?
|
| Synaptic Potentials | 1 | 2021 | 8 | 0.170 |
Why?
|
| Ceramides | 1 | 2021 | 43 | 0.170 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2000 | 5 | 0.170 |
Why?
|
| Nerve Endings | 1 | 2000 | 8 | 0.170 |
Why?
|
| Presenilin-1 | 1 | 2020 | 27 | 0.170 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 88 | 0.170 |
Why?
|
| Biguanides | 3 | 2009 | 7 | 0.160 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 235 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2020 | 77 | 0.160 |
Why?
|
| Alkanesulfonic Acids | 1 | 2020 | 8 | 0.160 |
Why?
|
| Axons | 1 | 2001 | 116 | 0.160 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 1066 | 0.160 |
Why?
|
| Mitochondria | 2 | 2017 | 516 | 0.160 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 928 | 0.160 |
Why?
|
| Calcitriol | 1 | 2019 | 32 | 0.160 |
Why?
|
| Fluorocarbons | 1 | 2020 | 28 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 159 | 0.150 |
Why?
|
| Xanthomonas | 1 | 2019 | 1 | 0.150 |
Why?
|
| Microbiological Techniques | 1 | 2019 | 13 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 68 | 0.150 |
Why?
|
| Berberine | 1 | 2018 | 8 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 68 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 101 | 0.150 |
Why?
|
| Lipid Metabolism | 5 | 2020 | 140 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 454 | 0.150 |
Why?
|
| Colitis | 1 | 2019 | 69 | 0.150 |
Why?
|
| DNA Repair | 1 | 2020 | 196 | 0.150 |
Why?
|
| Colon | 1 | 2019 | 118 | 0.140 |
Why?
|
| Nicotinic Antagonists | 3 | 2011 | 36 | 0.140 |
Why?
|
| Vitamin A Deficiency | 1 | 2017 | 13 | 0.140 |
Why?
|
| Female | 6 | 2025 | 24018 | 0.140 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2018 | 82 | 0.140 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 131 | 0.140 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2017 | 89 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 88 | 0.130 |
Why?
|
| Conditioning, Operant | 1 | 2017 | 90 | 0.130 |
Why?
|
| Calcium Signaling | 1 | 2018 | 108 | 0.130 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2011 | 81 | 0.130 |
Why?
|
| Cell Death | 1 | 2017 | 277 | 0.130 |
Why?
|
| Disease Progression | 1 | 2019 | 661 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 2017 | 181 | 0.130 |
Why?
|
| Universities | 2 | 2022 | 539 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 206 | 0.130 |
Why?
|
| Molecular Structure | 1 | 2017 | 560 | 0.120 |
Why?
|
| Environmental Pollutants | 2 | 2015 | 198 | 0.120 |
Why?
|
| Toxins, Biological | 1 | 2015 | 5 | 0.120 |
Why?
|
| Curriculum | 1 | 2018 | 311 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2021 | 501 | 0.110 |
Why?
|
| Ileum | 1 | 2014 | 16 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2015 | 28 | 0.110 |
Why?
|
| Cell Biology | 1 | 2014 | 13 | 0.110 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 102 | 0.110 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 67 | 0.110 |
Why?
|
| Cecum | 3 | 2020 | 17 | 0.110 |
Why?
|
| Research | 1 | 2015 | 177 | 0.100 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2020 | 190 | 0.100 |
Why?
|
| Sensory Gating | 1 | 2012 | 5 | 0.090 |
Why?
|
| Parvalbumins | 1 | 2012 | 17 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1188 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2015 | 303 | 0.090 |
Why?
|
| Peptide Mapping | 1 | 2011 | 20 | 0.090 |
Why?
|
| Selenoprotein P | 1 | 2012 | 45 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1559 | 0.090 |
Why?
|
| Interneurons | 1 | 2012 | 64 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2012 | 168 | 0.090 |
Why?
|
| Hybrid Cells | 2 | 2001 | 20 | 0.090 |
Why?
|
| Drug Interactions | 2 | 2011 | 151 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2015 | 574 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1112 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2011 | 88 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 189 | 0.090 |
Why?
|
| Ventral Tegmental Area | 1 | 2011 | 47 | 0.080 |
Why?
|
| Aged | 1 | 2023 | 7982 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 427 | 0.080 |
Why?
|
| Gossypium | 2 | 2021 | 5 | 0.080 |
Why?
|
| Apoptosis | 1 | 2017 | 1541 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 506 | 0.080 |
Why?
|
| Evoked Potentials | 1 | 2010 | 90 | 0.080 |
Why?
|
| Clostridium | 2 | 2019 | 24 | 0.080 |
Why?
|
| Acetylcholine | 2 | 2024 | 76 | 0.070 |
Why?
|
| Microdialysis | 1 | 2007 | 18 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 93 | 0.070 |
Why?
|
| Magnesium | 1 | 2007 | 93 | 0.070 |
Why?
|
| Dihydro-beta-Erythroidine | 2 | 2011 | 4 | 0.070 |
Why?
|
| Veratridine | 1 | 2006 | 1 | 0.060 |
Why?
|
| Quinpirole | 1 | 2006 | 18 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2006 | 48 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 34 | 0.060 |
Why?
|
| Sodium Channels | 1 | 2006 | 66 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2006 | 69 | 0.060 |
Why?
|
| Hawaii | 3 | 2018 | 2004 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2017 | 300 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2007 | 534 | 0.060 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2002 | 3 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2024 | 183 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2002 | 57 | 0.050 |
Why?
|
| Amines | 1 | 2002 | 40 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2002 | 39 | 0.050 |
Why?
|
| Acetates | 1 | 2002 | 29 | 0.050 |
Why?
|
| Capacity Building | 1 | 2022 | 99 | 0.050 |
Why?
|
| Gene Expression | 2 | 2015 | 692 | 0.050 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2021 | 3 | 0.040 |
Why?
|
| Diet | 2 | 2020 | 810 | 0.040 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2021 | 9 | 0.040 |
Why?
|
| Animal Experimentation | 1 | 2021 | 3 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2021 | 128 | 0.040 |
Why?
|
| Potassium Chloride | 1 | 2001 | 26 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2001 | 49 | 0.040 |
Why?
|
| Bradykinin | 1 | 2000 | 23 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 146 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2000 | 51 | 0.040 |
Why?
|
| Caffeine | 1 | 2000 | 28 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2001 | 105 | 0.040 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2021 | 65 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2001 | 70 | 0.040 |
Why?
|
| Long-Term Potentiation | 1 | 2021 | 109 | 0.040 |
Why?
|
| Potassium | 1 | 2000 | 109 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2000 | 198 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 2000 | 221 | 0.040 |
Why?
|
| Glioma | 1 | 2000 | 92 | 0.040 |
Why?
|
| Metabolome | 1 | 2020 | 50 | 0.040 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2000 | 135 | 0.040 |
Why?
|
| Bacteroidetes | 1 | 2019 | 13 | 0.040 |
Why?
|
| Poverty | 1 | 2022 | 395 | 0.040 |
Why?
|
| Kinetics | 1 | 2001 | 698 | 0.040 |
Why?
|
| Taurocholic Acid | 1 | 2018 | 5 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 75 | 0.040 |
Why?
|
| Amidohydrolases | 1 | 2018 | 12 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2021 | 355 | 0.040 |
Why?
|
| Seeds | 1 | 2019 | 46 | 0.040 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2018 | 14 | 0.040 |
Why?
|
| Plant Diseases | 1 | 2019 | 61 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2000 | 884 | 0.040 |
Why?
|
| Plant Leaves | 1 | 2019 | 134 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 308 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 145 | 0.030 |
Why?
|
| Point Mutation | 1 | 2018 | 98 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2017 | 76 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2020 | 973 | 0.030 |
Why?
|
| Conditioning, Classical | 1 | 2018 | 67 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2001 | 633 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 133 | 0.030 |
Why?
|
| Students | 1 | 2022 | 617 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 602 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2011 | 282 | 0.030 |
Why?
|
| Education, Medical | 1 | 2018 | 117 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 428 | 0.030 |
Why?
|
| Dioxins | 1 | 2015 | 8 | 0.030 |
Why?
|
| Indican | 1 | 2015 | 1 | 0.030 |
Why?
|
| Sulfuric Acid Esters | 1 | 2015 | 5 | 0.030 |
Why?
|
| Cresols | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 85 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 25 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2015 | 59 | 0.030 |
Why?
|
| Glucuronides | 1 | 2015 | 23 | 0.030 |
Why?
|
| Education, Graduate | 1 | 2014 | 30 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 71 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 295 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 134 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 165 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2014 | 74 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 580 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 279 | 0.030 |
Why?
|
| Glucose | 1 | 2015 | 242 | 0.030 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2014 | 93 | 0.030 |
Why?
|
| Aconitine | 1 | 2011 | 2 | 0.020 |
Why?
|
| GABA Agents | 1 | 2011 | 2 | 0.020 |
Why?
|
| 4-Aminopyridine | 1 | 2011 | 8 | 0.020 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2011 | 6 | 0.020 |
Why?
|
| Glutamate Decarboxylase | 1 | 2011 | 17 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 683 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 415 | 0.020 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2011 | 12 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2011 | 34 | 0.020 |
Why?
|
| Conotoxins | 1 | 2011 | 20 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2011 | 350 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1076 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2002 | 81 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2002 | 138 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 2002 | 228 | 0.010 |
Why?
|